Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202145 | 0.93 | EGFR (0.51) | EGFRLRRK2IGF1RKCNH2CDK1 | |
| SCHEMBL18239605 | 0.90 | EGFR (0.59) | EGFRLRRK2IGF1RKCNH2CDK1 | |
| SCHEMBL18239606 | 0.87 | EGFR (0.62) | EGFRIGF1RKCNH2 | |
| SCHEMBL18202345 | 0.85 | EGFR (0.43) | EGFRLRRK2KCNH2CDK1PTK2 | |
| SCHEMBL18202243 | 0.85 | EGFR (0.58) | EGFR | |
| SCHEMBL18202343 | 0.84 | EGFR (0.45) | EGFRLRRK2KCNH2CDK1CDK2 | |
| SCHEMBL19921295 | 0.84 | EGFR (0.42) | EGFRLRRK2KCNH2CDK1PTK2 | |
| SCHEMBL18202259 | 0.83 | EGFR (0.42) | EGFRLRRK2IGF1RKCNH2CDK1 | |
| SCHEMBL18202149 | 0.82 | EGFR (0.64) | EGFRIGF1RKCNH2 | |
| SCHEMBL18202150 | 0.81 | EGFR (0.56) | EGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885LRRK2 226/4885IGF1R 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.